# Myomo Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Myomo Inc). ## Overview Myomo, Inc. is a U.S.-based wearable medical robotics company that develops and markets the MyoPro line of custom-fabricated myoelectric upper-limb braces. Its devices are designed to help adults and adolescents with neuromuscular disorders or paralysis regain functional use of a weak or paralyzed arm in daily activities. ## Products & services • MyoPro myoelectric upper-limb orthosis • MyoPro 2X enhanced upper-limb brace • Custom fabrication, fitting and clinical support • Direct billing and reimbursement support services • O&P provider channel sales and consulting - **MyoPro devices** (85%) — Custom-fabricated myoelectric upper-limb braces that support weak or paralyzed arms and enable ADLs. - **Direct billing channel services** (10%) — Patient evaluation, fitting, reimbursement processing and insurance billing tied to direct-to-patient sales. - **O&P provider channel** (5%) — Sales and clinical support delivered through orthotics and prosthetics providers in the U.S. and abroad. - MyoPro myoelectric-controlled upper-limb orthosis - MyoPro 2X enhanced version launched in the U.S. - Custom fabrication, measurement, fitting and follow-up - Direct billing to insurers and Medicare - Sales through O&P providers, VA and international partners - Clinical consulting services for O&P channel support ## Customers Myomo sells primarily to patients with neuromuscular disorders and upper-limb paralysis, but the economic buyer is often an insurer or government health plan that reimburses the device. It also serves orthotics and prosthetics providers, the Veterans Administration, and rehabilitation hospitals that fit or recommend the product for eligible patients. Internationally, the company works with O&P providers and distributors in selected markets where regulatory approvals and reimbursement pathways exist. - **Direct-to-patient reimbursement pipeline** (primary) — Patients evaluated and fitted by Myomo or its clinical staff, with insurance authorization driving revenue recognition. - **Medicare Part B beneficiaries** (primary) — Patients served at published CMS fees, an important source of volume and faster revenue conversion. - **Orthotics and prosthetics providers** (secondary) — O&P practices that market, fit and support MyoPro devices, especially in the U.S. and Germany. - **Veterans Administration** (secondary) — VA-related sales for eligible veterans who need upper-limb functional assistance. - **International patients and providers** (emerging) — Customers in Europe, Canada and Australia served through regulatory approvals and local provider relationships. - Adults with stroke, TBI, spinal cord injury or brachial plexus injury - Adolescents with neuromuscular conditions needing upper-limb support - Insurance companies and Medicare as reimbursement payers - Orthotics and prosthetics providers that evaluate and fit patients - Veterans Administration and rehabilitation hospitals - International O&P partners in Europe, Australia and Canada ## Geography Myomo is headquartered in the United States and generates most revenue there through direct billing, Medicare and U.S. O&P channels. It also sells in Europe, Canada and Australia, and has specifically highlighted Germany as an important international market. The company has obtained EU market access for MyoPro, a Canadian medical device license, and provider agreements in the U.K., Denmark, Germany, Italy and Australia, while its China joint venture has been disrupted by partner bankruptcy. - United States is the core market and main revenue source - Germany is a key European market for O&P channel growth - Europe and Australia are served through provider relationships - Canada is enabled by a medical device license - China exposure exists through a joint venture that was disrupted - International expansion depends on reimbursement and regulatory access ## Strategy Myomo is focused on expanding recurring revenue sources, especially through its MyoConnect referral program and a larger U.S. O&P channel. It is also investing in direct-billing capacity, advertising, clinical headcount and manufacturing support to shorten cycle times and convert more patients into revenue. Product development remains important, highlighted by the launch of MyoPro 2X and continued R&D spending to support new and sustaining products. - **Expand direct billing and patient acquisition efficiency** (short-term) — Direct billing is the largest revenue channel, so lower acquisition cost and faster conversion improve scale and cash generation. - **Build the U.S. O&P channel** (medium-term) — O&P providers can broaden reach and reduce dependence on advertising-driven direct-to-patient demand. - **Expand recurring referral sources** (medium-term) — Referrals from rehab clinics and stroke centers can create a steadier patient pipeline and improve operating leverage. - **Develop and launch improved products** (medium-term) — Newer devices can support pricing, clinical differentiation and competitive defense. - Grow MyoConnect referrals from rehab clinics and stroke centers - Expand U.S. O&P channel revenue and partner coverage - Increase direct-billing capacity and reduce patient acquisition cost - Invest in R&D for sustaining and new product development - Support international growth through regulatory access and partners - Improve cycle times so more authorizations convert to revenue ## Risks Myomo depends on reimbursement approvals, patient acceptance and a limited set of clinical and supplier relationships, so demand can be volatile and operational disruptions can quickly affect revenue. It also faces intense competition from medical robotics and O&P companies, plus regulatory and intellectual property risk in a niche market where published billing fees may attract new entrants. International expansion adds country-specific reimbursement, partner and geopolitical exposure, including the disruption of its China joint venture. - **Reimbursement dependence** [high] — Revenue recognition and patient demand rely on insurance authorization, Medicare coverage and payer payment behavior. - **Patient adoption and access barriers** [high] — Patients may resist wearing an external device or face health, social or economic barriers to evaluation and fitting. - **Supplier concentration** [high] — The company depends on a single third party for key subassemblies and limited suppliers for components. - **Competitive pressure** [medium] — Competitors can respond with lower-cost or more effective devices, especially after billing fees become public. - **China joint venture disruption** [medium] — The Ryzur Medical bankruptcy severely limited JV operations and may reduce expected international expansion value. - Revenue depends on insurance and Medicare reimbursement decisions - Patient resistance and co-pay burden can slow device adoption - Single-source and limited-source suppliers create supply risk - Competition may intensify after CMS fee publication - IP disputes or regulatory actions could limit commercialization - China JV disruption shows partner and geopolitical exposure ## Accounting The most important accounting judgment is revenue recognition, especially for Medicare Part B and other payers where transaction pricing depends on estimated payments and authorization timing. Because revenue can be recognized at delivery for some patients but only after authorization or documentation for others, quarterly results can shift materially with backlog conversion and payer mix. Investors should also watch derivative liabilities, warranty reserves, inventory obsolescence and stock-based compensation, all of which can affect reported earnings and balance sheet volatility. - **Revenue recognition timing and transaction pricing** — Can materially change quarterly revenue and gross margin - **Derivative liabilities** — Affects reported net loss and earnings volatility - **Warranty obligations and reserves** — Affects cost of revenue and gross margin - **Inventory and slow-moving reserves** — Can reduce gross profit if reserves increase - **Stock-based compensation and valuation allowances** — Affects operating expenses and equity-related disclosures - Revenue recognition depends on payer-specific payment estimates - Medicare Part B revenue may be recognized at delivery - Backlog and authorization timing can shift quarterly revenue - Derivative liabilities can create non-cash fair value swings - Warranty and inventory reserves affect gross margin - Stock-based compensation and valuation allowances affect expenses --- *Last updated: 2026-09-24T12:28:33.809775+00:00*